Jeffrey S. Glenn, Director at Eiger BioPharmaceuticals, Inc. (EIGR), bought 15,000 shares at $9.53 ($143K) on 2017-09-01, disclosed to the SEC on 2017-09-05.
Open-market purchase of $143k EIGR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| EIGR | BUY | 2020-03-17 | $151K | — | Filing → |
| EIGR | BUY | 2016-11-21 | $197K | — | Filing → |